即时检测对南非性传播感染管理的影响:来自HVTN702艾滋病病毒疫苗试验的证据
研究比较南非HVTN702试验中即时检测与中心实验室检测对淋球菌/沙眼衣原体及阴道毛滴虫治疗启动和不良事件报告时间的影响。959名女性中,即时检测组淋球菌/沙眼衣原体治疗启动和不良事件报告均显著快于中心实验室组,阴道毛滴虫检测两组无显著差异。即时检测有助于及时管理性传播感染。
要点
- 即时检测组淋球菌/沙眼衣原体治疗启动中位时间0.20天,中心实验室组14.22天(P<.001)。
- 即时检测组淋球菌/沙眼衣原体不良事件报告中位时间0.24天,中心实验室组15.12天(P<.001)。
- 阴道毛滴虫治疗启动和不良事件报告时间两组无显著差异(P>.05)。
核心结论
- 即时检测可促进性传播感染的及时管理,具有潜在治疗和预防益处,突显其在资源有限环境中作为诊断工具的效用。
研究设计与样本
- 研究纳入HVTN702试验在南非的959名女性,中位年龄23岁(四分位距21-26岁),比较即时检测与中心实验室检测对性传播感染治疗启动和不良事件报告的影响。
主要发现
- 淋球菌/沙眼衣原体治疗启动中位天数(95%CI)在eThekwini为0.20(0.16-0.25),在Verulam/Isipingo为14.22(14.12-15.09)(P<.001)。
- 淋球菌/沙眼衣原体不良事件报告中位天数(95%CI)在eThekwini为0.24(0.19-0.27),在Verulam/Isipingo为15.12(13.22-21.24)(P<.001)。
- 阴道毛滴虫治疗启动中位天数(95%CI)在eThekwini为0.17(0.12-0.27),在Verulam/Isipingo为0.18(0.15-0.2)(P>.05)。
- 阴道毛滴虫不良事件报告中位天数(95%CI)在eThekwini为0.25(0.20-0.99),在Verulam/Isipingo为0.24(0.15-0.99)(P>.05)。
- Cox回归显示eThekwini较Verulam/Isipingo淋球菌/沙眼衣原体治疗启动更快(aHR 39.62,95%CI 15.13-103.74),不良事件报告更快(aHR 3.38,95%CI 2.23-5.13);阴道毛滴虫治疗启动(aHR 0.93,95%CI 0.59-1.48)和不良事件报告(aHR 1.38,95%CI 0.86-2.21)相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Alternative approaches to syndromic management are needed to reduce rates of sexually transmitted infections (STIs) in resource-limited settings. We investigated the impact of point-of-care (POC) versus central laboratory-based testing on STI treatment initiation and STI adverse event (STI-AE) reporting. METHODS: We used Kaplan-Meier and Cox regression models to compare times to treatment initiation and STI-AE reporting among HVTN702 trial participants in South Africa. Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT) were diagnosed POC at eThekwini clinic and in a central laboratory at Verulam/Isipingo clinics. All clinics used POC assays for Trichomonas vaginalis (TV) testing. RESULTS: Among 959 women (median age, 23 [interquartile range, 21-26] years), median days (95% confidence interval [95%CI]) to NG/CT treatment initiation and NG/CT-AE reporting were 0.20 (.16-.25) and 0.24 (.19-.27) at eThekwini versus 14.22 (14.12-15.09) and 15.12 (13.22-21.24) at Verulam/Isipingo (all P < .001). Median days (95%CI) to TV treatment initiation and TV-AE reporting were 0.17 (.12-.27) and 0.25 (.20-.99) at eThekwini versus 0.18 (.15-.2) and 0.24 (.15-.99) at Verulam/Isipingo (all P > .05). Cox regression analysis revealed that NG/CT treatment initiation (adjusted hazard ratio [aHR], 39.62 [95%CI, 15.13-103.74]) and NG/CT-AE reporting (aHR, 3.38 [95%CI, 2.23-5.13]) occurred faster at eThekwini versus Verulam/Isipingo, while times to TV treatment initiation (aHR, 0.93 [95%CI, .59-1.48]) and TV-AE reporting (aHR, 1.38 [95%CI, .86-2.21]) were similar. CONCLUSIONS: POC testing led to prompt STI management with potential therapeutic and prevention benefits, highlighting its utility as a diagnostic tool in resource-limited settings.
引用
- Asare K, Andine T, Naicker N, et al. Impact of Point-of-Care Testing on the Management of Sexually Transmitted Infections in South Africa: Evidence from the HVTN702 Human Immunodeficiency Virus Vaccine Trial. Clin Infect Dis. 2023. PMID: 36250382. doi:10.1093/cid/ciac824
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。